CH626634A5 - Process for the preparation of pregnane derivatives - Google Patents

Process for the preparation of pregnane derivatives Download PDF

Info

Publication number
CH626634A5
CH626634A5 CH1101177A CH1101177A CH626634A5 CH 626634 A5 CH626634 A5 CH 626634A5 CH 1101177 A CH1101177 A CH 1101177A CH 1101177 A CH1101177 A CH 1101177A CH 626634 A5 CH626634 A5 CH 626634A5
Authority
CH
Switzerland
Prior art keywords
formula
esterified
hydroxyl group
groups
compound
Prior art date
Application number
CH1101177A
Other languages
German (de)
Inventor
Andor Dr Fuerst
Ludwig Dr Labler
Werner Dr Meier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to CH1101177A priority Critical patent/CH626634A5/en
Priority to IT28417/77A priority patent/IT1088094B/en
Priority to FR7730516A priority patent/FR2367776A1/en
Priority to US05/841,430 priority patent/US4193921A/en
Priority to NL7711245A priority patent/NL7711245A/en
Priority to GB10700/78A priority patent/GB1568735A/en
Priority to DE19772746107 priority patent/DE2746107A1/en
Priority to AT732877A priority patent/AT359220B/en
Priority to GB42652/77A priority patent/GB1568734A/en
Priority to JP12256077A priority patent/JPS5350152A/en
Publication of CH626634A5 publication Critical patent/CH626634A5/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Pregnane derivatives which can be used for the preparation of cholecalciferol derivatives and have the formula <IMAGE> in which R<1> and R<3> are a hydroxyl group or an etherified or esterified hydroxyl group which can easily be cleaved to give a hydroxyl group, are prepared by esterification of a 21-hydroxyl group and optional etherification, esterification or ether cleavage in position 1,3.

Description

       

  
 

**WARNUNG** Anfang DESC Feld konnte Ende CLMS uberlappen **.

 



   PATENTANSPRÜCHE 1. Verfahren zur Herstellung von Verbindungen der Formel
EMI1.1     
 worin R1 und R3 eine Hydroxygruppe oder eine leicht zur Hydroxygruppe spaltbare verätherte oder veresterte Hydroxygruppe und R21 eine leicht spaltbare veresterte Hydroxygruppe bedeuten, dadurch gekennzeichnet, dass man in einer Verbindung der Formel
EMI1.2     
 die Hydroxygruppe in 21-Stellung verestert.



   2. Verfahren nach Anspruch 1, zur Herstellung einer Verbindung der Formel I, worin R1 und R3 eine leicht zur Hydroxygruppe spaltbare verätherte oder veresterte Hydroxygruppe ist, dadurch gekennzeichnet, dass man ein aus einer Verbindung der Formel II erhaltenes 1,3-Diol der Formel I veräthert oder verestert.



   3. Verfahren nach Anspruch 1, zur Herstellung eines 1,3-Diols der Formel I, dadurch gekennzeichnet, dass man in einem nach dem Verfahren von Anspruch 1 erhaltenen 1,3-Diäther die Äthergruppen abspaltet.



   4. Verfahren nach Anspruch 2, dadurch gekennzeichnet, dass man ein 1,3-Diol der Formel I diacetyliert.



   Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von neuen   Pregnanderivaten    der Formel
EMI1.3     
 worin R1 und R3 eine Hydroxygruppe oder eine leicht zur Hydroxygruppe spaltbare verätherte oder veresterte Hydroxygruppe; und R20 eine leicht spaltbare veresterte Hydroxymethylgruppe bedeutet.



   Im Rahmen der vorliegenden Erfindung sind Äthergruppen, die sich leicht, d. h., ohne Veränderung an anderen Stellen des Moleküls spalten lassen, beispielsweise solche der Formel   RXO-C(RJ,RZ > O-,    wobei RJ Wasserstoff oder   Cl-6-Alkyl,    Rx und   RZ      Ci s-Alkyl    oder Rx und   RZ    gemeinsam   C3-6-Alkylen    bedeuten. Beispiele für solche Reste sind Tetrahydropyran2-yloxy, Methoxymethoxy. Beispiele veresterter Hydroxygruppen R1 und R3 sind Formyloxy und   C2X-Alkanoyloxy-    gruppen wie Acetoxy. Beispiele veresterter Hydroxymethylgruppen R20 sind Formyloxymethyl- und   C24-Alkanoyloxy-    methylgruppen, wie Acetoxymethyl, sowie Brommethyl und p-Toluolsulfonyloxymethyl.



   Die Verbindungen der Formel I werden erfindungsgemäss dadurch hergestellt, dass man in einer Verbindung der Formel
EMI1.4     
 die Hydroxymethylgruppe in 20-Stellung verestert.



   Die Verbindungen der Formel II können wie in der deutschen Offenlegungsschrift 2 746 107 beschrieben hergestellt werden.



   In einer Verbindung der Formel I enthaltene freie 1- und 3-Hydroxygruppen können veräthert oder verestert werden, z.B. durch Behandlung mit Dihydropyran in Gegenwart katalytischer Mengen p-Toluolsulfonsäure (zwecks Herstellung eines Tetrahydropyranyläthers) oder durch Behandlung mit einem Säureanhydrid wie Acetanhydrid, in Gegenwart einer Base, wie Pyridin (zwecks Herstellung des 3-Mono- oder 1,3-Diacetats). Andererseits können Äthergruppen in 1- und 3-Stellung einer Verbindung der Formel I, z.B. durch Behandlung mit Säuren, abgespalten werden.



   Die Verbindungen der Formel I sind Zwischenprodukte für die Herstellung von Derivaten des Cholecalciferols (Vit  



  amin D3), z. B. von   la-Hydroxycholecalciferol    und   1a,25-Di-    hydroxycholecalciferol.



   Beispiel 1
Zu einer Lösung von 100 mg   (20S)-la,3P-Diacetoxy-21-    hydroxy-20-methyl-pregn-5-en in 0,5 ml trockenem Pyridin wurde bei 0       eine Lösung von 55,1 mg p-Toluolsulfonsäurechlorid in 0,2 ml trockenem Pyridin zugefügt. Nach 6 Stunden Belassen bei   0     wurde das Gemisch auf Eiswasser gegossen und mit Äther extrahiert. Der Extrakt wurde der Reihe nach mit 2N Salzsäure, Wasser, gesättigter   NaHCO3-Lösung    und Wasser gewaschen. Der nach Trocknen über Natriumsulfat und Einengen resultierende Rückstand ergab durch Chromatographie an 3,5 g Kieselgel mit Hexan/Äther 4:1 100 mg einheitliches   (20S)-la,3ss-Diacetoxy-20-methyl-21-p-toluol-    sulfonyloxy-pregn-5-en. 

  Das Produkt schmolz nach Umkristallisation aus Äther bei   168-170 ;    [a]D   = 20,80    (c = 0,5,   CHCl3).   



   Beispiel 2
Eine Lösung von 0,54 g   (20S)-la,3 P-Diacetoxy-21-    hydroxy-20-methyl-pregn-5-en und 0,825 g Tetrabromkohlenstoff in 10 ml Äther wurde mit 0,625 g Triphenylphosphin versetzt und das Gemisch 16 Stunden bei Raumtemperatur belassen. Nach Verdünnen mit Äther wird von unlöslichem Material abfiltriert. Das Filtrat wird im Vakuum eingeengt und der Rückstand an 15 g Kieselgel mit Hexan/Äther 9:1 chromatographiert. Es resultierten 0,55 g einheitliches (20S)   21-Brom-la,3ss-diacetoxy-20-methyl-pregn-5-en    als farbloses Pulver vom Schmelzpunkt   75-76 " ;    [a]D   = -13,8"    (c =   0,5,CHCb).    



  
 

** WARNING ** beginning of DESC field could overlap end of CLMS **.

 



   PATENT CLAIMS 1. Process for the preparation of compounds of the formula
EMI1.1
 wherein R1 and R3 represent a hydroxyl group or an etherified or esterified hydroxyl group which is easily cleavable to the hydroxyl group and R21 is an easily cleavable esterified hydroxyl group, characterized in that in a compound of the formula
EMI1.2
 the hydroxy group esterified in the 21-position.



   2. The method according to claim 1, for the preparation of a compound of formula I, wherein R1 and R3 is an ethereal or esterified hydroxy group which is easily cleavable to the hydroxyl group, characterized in that a 1,3-diol of the formula obtained from a compound of the formula II I etherified or esterified.



   3. The method according to claim 1, for the preparation of a 1,3-diol of the formula I, characterized in that the ether groups are split off in a 1,3-diether obtained by the process of claim 1.



   4. The method according to claim 2, characterized in that a 1,3-diol of the formula I is diacetylated.



   The present invention relates to a process for the preparation of new prognane derivatives of the formula
EMI1.3
 wherein R1 and R3 are a hydroxyl group or an etherified or esterified hydroxyl group which is easily cleavable to the hydroxyl group; and R20 represents an easily cleavable esterified hydroxymethyl group.



   Within the scope of the present invention, ether groups that are easily, i. that is, can be cleaved at other positions in the molecule without modification, for example those of the formula RXO-C (RJ, RZ> O-, where RJ is hydrogen or Cl-6-alkyl, Rx and RZ Ci s-alkyl or Rx and RZ together C3-6-alkylene. Examples of such radicals are tetrahydropyran2-yloxy, methoxymethoxy. Examples of esterified hydroxyl groups R1 and R3 are formyloxy and C2X-alkanoyloxy groups such as acetoxy. Examples of esterified hydroxymethyl groups R20 are formyloxymethyl and C24-alkanoyloxy-methyl groups, such as Acetoxymethyl, as well as bromomethyl and p-toluenesulfonyloxymethyl.



   According to the invention, the compounds of the formula I are prepared by reacting in a compound of the formula
EMI1.4
 the hydroxymethyl group is esterified in the 20-position.



   The compounds of formula II can be prepared as described in German Offenlegungsschrift 2,746,107.



   Free 1- and 3-hydroxy groups contained in a compound of formula I can be etherified or esterified, e.g. by treatment with dihydropyran in the presence of catalytic amounts of p-toluenesulfonic acid (to produce a tetrahydropyranyl ether) or by treatment with an acid anhydride such as acetic anhydride in the presence of a base such as pyridine (to produce 3-mono- or 1,3-diacetate). On the other hand, ether groups in the 1- and 3-position of a compound of formula I, e.g. by treatment with acids.



   The compounds of formula I are intermediates for the preparation of derivatives of cholecalciferol (Vit



  amine D3), e.g. B. of la-hydroxycholecalciferol and 1a, 25-di-hydroxycholecalciferol.



   example 1
A solution of 55.1 mg of p-toluenesulfonic acid chloride was added to a solution of 100 mg (20S) -la, 3P-diacetoxy-21-hydroxy-20-methyl-pregn-5-ene in 0.5 ml of dry pyridine at 0 0.2 ml of dry pyridine added. After 6 hours at 0 the mixture was poured onto ice water and extracted with ether. The extract was washed in sequence with 2N hydrochloric acid, water, saturated NaHCO3 solution and water. The residue resulting from drying over sodium sulfate and concentration gave by chromatography on 3.5 g of silica gel with hexane / ether 4: 1 100 mg of uniform (20S) -la, 3ss-diacetoxy-20-methyl-21-p-toluene-sulfonyloxy- pregn-5-en.

  The product melted after recrystallization from ether at 168-170; [a] D = 20.80 (c = 0.5, CHCl3).



   Example 2
A solution of 0.54 g (20S) -la, 3 P-diacetoxy-21-hydroxy-20-methyl-pregn-5-ene and 0.825 g of carbon tetrabromo in 10 ml of ether was mixed with 0.625 g of triphenylphosphine and the mixture for 16 hours leave at room temperature. After dilution with ether, insoluble material is filtered off. The filtrate is concentrated in vacuo and the residue is chromatographed on 15 g of silica gel with hexane / ether 9: 1. This gave 0.55 g of uniform (20S) 21-bromo-la, 3ss-diacetoxy-20-methyl-pregn-5-ene as a colorless powder with a melting point of 75-76 "; [a] D = -13.8" ( c = 0.5, CHCb).


    

Claims (4)

PATENTANSPRÜCHE 1. Verfahren zur Herstellung von Verbindungen der Formel EMI1.1 worin R1 und R3 eine Hydroxygruppe oder eine leicht zur Hydroxygruppe spaltbare verätherte oder veresterte Hydroxygruppe und R21 eine leicht spaltbare veresterte Hydroxygruppe bedeuten, dadurch gekennzeichnet, dass man in einer Verbindung der Formel EMI1.2 die Hydroxygruppe in 21-Stellung verestert.  PATENT CLAIMS 1. Process for the preparation of compounds of the formula EMI1.1  wherein R1 and R3 represent a hydroxyl group or an etherified or esterified hydroxyl group which is easily cleavable to the hydroxyl group and R21 is an easily cleavable esterified hydroxyl group, characterized in that in a compound of the formula EMI1.2  the hydroxy group esterified in the 21-position. 2. Verfahren nach Anspruch 1, zur Herstellung einer Verbindung der Formel I, worin R1 und R3 eine leicht zur Hydroxygruppe spaltbare verätherte oder veresterte Hydroxygruppe ist, dadurch gekennzeichnet, dass man ein aus einer Verbindung der Formel II erhaltenes 1,3-Diol der Formel I veräthert oder verestert.  2. The method according to claim 1, for the preparation of a compound of formula I, wherein R1 and R3 is an ethereal or esterified hydroxy group which is easily cleavable to the hydroxyl group, characterized in that a 1,3-diol of the formula obtained from a compound of the formula II I etherified or esterified. 3. Verfahren nach Anspruch 1, zur Herstellung eines 1,3-Diols der Formel I, dadurch gekennzeichnet, dass man in einem nach dem Verfahren von Anspruch 1 erhaltenen 1,3-Diäther die Äthergruppen abspaltet.  3. The method according to claim 1, for the preparation of a 1,3-diol of the formula I, characterized in that the ether groups are split off in a 1,3-diether obtained by the process of claim 1. 4. Verfahren nach Anspruch 2, dadurch gekennzeichnet, dass man ein 1,3-Diol der Formel I diacetyliert.  4. The method according to claim 2, characterized in that a 1,3-diol of the formula I is diacetylated. Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von neuen Pregnanderivaten der Formel EMI1.3 worin R1 und R3 eine Hydroxygruppe oder eine leicht zur Hydroxygruppe spaltbare verätherte oder veresterte Hydroxygruppe; und R20 eine leicht spaltbare veresterte Hydroxymethylgruppe bedeutet.  The present invention relates to a process for the preparation of new prognane derivatives of the formula EMI1.3  wherein R1 and R3 are a hydroxyl group or an etherified or esterified hydroxyl group which is easily cleavable to the hydroxyl group; and R20 represents an easily cleavable esterified hydroxymethyl group. Im Rahmen der vorliegenden Erfindung sind Äthergruppen, die sich leicht, d. h., ohne Veränderung an anderen Stellen des Moleküls spalten lassen, beispielsweise solche der Formel RXO-C(RJ,RZ > O-, wobei RJ Wasserstoff oder Cl-6-Alkyl, Rx und RZ Ci s-Alkyl oder Rx und RZ gemeinsam C3-6-Alkylen bedeuten. Beispiele für solche Reste sind Tetrahydropyran2-yloxy, Methoxymethoxy. Beispiele veresterter Hydroxygruppen R1 und R3 sind Formyloxy und C2X-Alkanoyloxy- gruppen wie Acetoxy. Beispiele veresterter Hydroxymethylgruppen R20 sind Formyloxymethyl- und C24-Alkanoyloxy- methylgruppen, wie Acetoxymethyl, sowie Brommethyl und p-Toluolsulfonyloxymethyl.  Within the scope of the present invention, ether groups that are easily, i. that is, can be cleaved at other points in the molecule without modification, for example those of the formula RXO-C (RJ, RZ> O-, where RJ is hydrogen or Cl-6-alkyl, Rx and RZ Ci s-alkyl or Rx and RZ together C3-6-alkylene. Examples of such radicals are tetrahydropyran2-yloxy, methoxymethoxy. Examples of esterified hydroxyl groups R1 and R3 are formyloxy and C2X-alkanoyloxy groups such as acetoxy. Examples of esterified hydroxymethyl groups R20 are formyloxymethyl and C24-alkanoyloxy-methyl groups, such as Acetoxymethyl, as well as bromomethyl and p-toluenesulfonyloxymethyl. Die Verbindungen der Formel I werden erfindungsgemäss dadurch hergestellt, dass man in einer Verbindung der Formel EMI1.4 die Hydroxymethylgruppe in 20-Stellung verestert.  According to the invention, the compounds of the formula I are prepared by reacting in a compound of the formula EMI1.4  the hydroxymethyl group is esterified in the 20-position.   Die Verbindungen der Formel II können wie in der deutschen Offenlegungsschrift 2 746 107 beschrieben hergestellt werden.  The compounds of formula II can be prepared as described in German Offenlegungsschrift 2,746,107. In einer Verbindung der Formel I enthaltene freie 1- und 3-Hydroxygruppen können veräthert oder verestert werden, z.B. durch Behandlung mit Dihydropyran in Gegenwart katalytischer Mengen p-Toluolsulfonsäure (zwecks Herstellung eines Tetrahydropyranyläthers) oder durch Behandlung mit einem Säureanhydrid wie Acetanhydrid, in Gegenwart einer Base, wie Pyridin (zwecks Herstellung des 3-Mono- oder 1,3-Diacetats). Andererseits können Äthergruppen in 1- und 3-Stellung einer Verbindung der Formel I, z.B. durch Behandlung mit Säuren, abgespalten werden.  Free 1- and 3-hydroxy groups contained in a compound of formula I can be etherified or esterified, e.g. by treatment with dihydropyran in the presence of catalytic amounts of p-toluenesulfonic acid (to produce a tetrahydropyranyl ether) or by treatment with an acid anhydride such as acetic anhydride in the presence of a base such as pyridine (to produce 3-mono- or 1,3-diacetate). On the other hand, ether groups in the 1- and 3-position of a compound of formula I, e.g. by treatment with acids. Die Verbindungen der Formel I sind Zwischenprodukte für die Herstellung von Derivaten des Cholecalciferols (Vit **WARNUNG** Ende CLMS Feld konnte Anfang DESC uberlappen**.  The compounds of formula I are intermediates for the preparation of derivatives of cholecalciferol (Vit ** WARNING ** End of CLMS field could overlap beginning of DESC **.
CH1101177A 1976-10-14 1977-09-08 Process for the preparation of pregnane derivatives CH626634A5 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CH1101177A CH626634A5 (en) 1977-09-08 1977-09-08 Process for the preparation of pregnane derivatives
IT28417/77A IT1088094B (en) 1976-10-14 1977-10-10 DERIVATIVES OF THE PREGNANO
FR7730516A FR2367776A1 (en) 1976-10-14 1977-10-11 NEW DERIVATIVES OF PREGNANE USEFUL IN PARTICULAR IN THE SYNTHESIS OF VITAMIN D3
US05/841,430 US4193921A (en) 1976-10-14 1977-10-12 Pregnane derivatives
NL7711245A NL7711245A (en) 1976-10-14 1977-10-13 PROCESS FOR PREPARING PREGNAN DERIVATIVES.
GB10700/78A GB1568735A (en) 1976-10-14 1977-10-13 Pregnane derivatives
DE19772746107 DE2746107A1 (en) 1976-10-14 1977-10-13 PREGNANDERIVATES
AT732877A AT359220B (en) 1976-10-14 1977-10-13 METHOD FOR PRODUCING NEW PREGNANE DERIVATIVES
GB42652/77A GB1568734A (en) 1976-10-14 1977-10-13 Pregnane derivatives
JP12256077A JPS5350152A (en) 1976-10-14 1977-10-14 Pregnane derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1101177A CH626634A5 (en) 1977-09-08 1977-09-08 Process for the preparation of pregnane derivatives

Publications (1)

Publication Number Publication Date
CH626634A5 true CH626634A5 (en) 1981-11-30

Family

ID=4369120

Family Applications (1)

Application Number Title Priority Date Filing Date
CH1101177A CH626634A5 (en) 1976-10-14 1977-09-08 Process for the preparation of pregnane derivatives

Country Status (1)

Country Link
CH (1) CH626634A5 (en)

Similar Documents

Publication Publication Date Title
DE2715863A1 (en) PROCESS FOR THE PRODUCTION OF STEROID CARBONIC ACIDS AND THEIR ESTERS
EP0572489B1 (en) Starting compounds for preparing calcitriol and its derivatives, method for preparing these starting compounds and intermediate products for this method
DE2746107A1 (en) PREGNANDERIVATES
DE2257533A1 (en) TOTAL SYNTHESIS OF PROSTAGLANDIN E LOW 1
CH626634A5 (en) Process for the preparation of pregnane derivatives
DE2347172A1 (en) PROSTAGLANDIN E DEEP 1 SYNTHESIS
EP0044495B1 (en) 16-beta ethyl steroids, compositions containing them and process for their preparation
AT205679B (en) Process for making 3, 11, 17-substituted steroids
DE3639583A1 (en) METHOD FOR PRODUCING THE APOVINCAMINE ACID ETHYL ESTER
DE958841C (en) Process for the preparation of 4, 17 (20) -pregnadiene-11ª ‡ (or 11ª ‰), -21-diol-3-one
CH630393A5 (en) Process for preparating steroid carboxylic acid salts and steroid carboxylic acid esters
AT235480B (en) Process for the production of new steroid compounds
DE960819C (en) Process for the production of 11ª ‰ -oxyprogesterone
CH323171A (en) Process for the production of new 14-methyl steroids
DE1160434B (en) Process for the preparation of therapeutically active steroid compounds
DE2429644B2 (en) PROCESS FOR THE PRODUCTION OF DESMOSTEROL, WHOSE HYDROXYL GROUP IS PROTECTED IN 3-POSITION, IF NECESSARY
CH508611A (en) Process for the 17a-alkylation of 20-keto steroids of the pregnane series
CH623338A5 (en)
CH520132A (en) Oestrogen water-soluble conjugates
CH356767A (en) Method of making steroids
CH380116A (en) Process for the production of new cyclosteroids
DE1193041B (en) Process for making delta 7, delta 7.9, (11), delta 7.9, (11), 16, delta 7, delta 8 or delta 8.16 steroids
DE1593363B1 (en) Process for the production of 19-nor-delta? -3-keto-steroids of the androstane series, the pregnane series or the cholestane series
CH632520A5 (en) Process for the preparation of novel pregnane derivatives
DE1147942B (en) Process for the preparation of 16ª ‡, 17ª ‡ - (1-alkoxy) -alkylidene dioxysteroids

Legal Events

Date Code Title Description
PL Patent ceased